Attached files
| file | filename |
|---|---|
| EX-10.5 - EXHIBIT 10.5 - Hepion Pharmaceuticals, Inc. | tm2034164d1_ex10-5.htm |
| EX-10.4 - EXHIBIT 10.4 - Hepion Pharmaceuticals, Inc. | tm2034164d1_ex10-4.htm |
| S-1 - FORM S-1 - Hepion Pharmaceuticals, Inc. | tm2034164-1_s1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Hepion Pharmaceuticals, Inc.
Edison, New Jersey
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated May 14, 2020, relating to the consolidated financial statements of Hepion Pharmaceuticals, Inc., which is incorporated by reference in that Prospectus. Our report on the consolidated financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP
Woodbridge, New Jersey
October 29, 2020